Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial

医学 伦瓦提尼 彭布罗利珠单抗 肾细胞癌 临床终点 人口 不利影响 临床研究阶段 肿瘤科 内科学 临床试验 免疫疗法 癌症 环境卫生 甲状腺癌
作者
Laurence Albigès,Howard Gurney,Vagif Atduev,Cristina Suárez,Miguel Ángel Climent,David Pook,Piotr Tomczak,Philippe Barthélémy,Jae‐Lyun Lee,V.P. Stus,Thomas Ferguson,Paweł Wiechno,Erhan Gökmen,Louis Lacombe,Craig Gedye,Rodolfo F. Perini,Manish Sharma,Xiang Peng,Chung‐Han Lee
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:24 (8): 881-891 被引量:145
标识
DOI:10.1016/s1470-2045(23)00276-0
摘要

Immunotherapy-based combinations including pembrolizumab plus lenvatinib are the standard of care for patients with first-line clear-cell renal cell carcinoma, but these combinations are not well characterised in non-clear-cell renal cell carcinoma. We aimed to assess the activity and safety of pembrolizumab plus lenvatinib as a first-line treatment for patients with advanced non-clear-cell renal cell carcinoma.KEYNOTE-B61 is a single-arm, phase 2 trial being conducted at 48 sites (hospitals and cancer centres) in 14 countries (Australia, Canada, France, Hungary, Ireland, Italy, Poland, South Korea, Russia, Spain, Türkiye, Ukraine, the UK, and the USA). Adult patients (aged ≥18 years) with previously untreated stage IV non-clear-cell renal cell carcinoma and a Karnofsky performance status of 70% or higher were eligible for enrolment. All enrolled patients received pembrolizumab 400 mg intravenously every 6 weeks for up to 18 cycles (2 years) plus lenvatinib 20 mg orally once daily or until disease progression, unacceptable toxicity, or withdrawal; lenvatinib could be continued beyond 2 years. The primary endpoint was the proportion of patients with a confirmed objective response as per adjusted Response Evaluation Criteria in Solid Tumours (version 1.1) assessed by independent central review. Activity and safety were analysed in all patients who received at least one dose of study treatment (the as-treated population). This trial is registered with ClinicalTrials.gov (NCT04704219) and is no longer recruiting participants but is ongoing.Between Feb 23, 2021, and Jan 21, 2022, 215 patients were screened; 158 were enrolled and received treatment. Median age at baseline was 60 years (IQR 52-69), 112 (71%) of 158 patients were male, 46 (29%) were female, 128 (81%) were White, 12 (8%) were Asian, three (2%) were Black or African American, and 15 (9%) were missing data on race. As of data cutoff (Nov 7, 2022), median study follow-up was 14·9 months (IQR 11·1-17·4). 78 of 158 patients had a confirmed objective response (49%; 95% CI 41-57), including nine (6%) patients with a confirmed complete response and 69 (44%) with a confirmed partial response. Grade 3-4 treatment-related adverse events occurred in 81 (51%) of 158 patients, the most common of which were hypertension (37 [23%] of 158), proteinuria (seven [4%]), and stomatitis (six [4%]). Serious treatment-related adverse events occurred in 31 (20%) of 158 patients. Eight (5%) patients died due to adverse events, none of which was considered related to the treatment by the investigators (one each of cardiac failure, peritonitis, pneumonia, sepsis, cerebrovascular accident, suicide, pneumothorax, and pulmonary embolism).Pembrolizumab plus lenvatinib has durable antitumour activity in patients with previously untreated advanced non-clear-cell renal cell carcinoma, with a safety profile consistent with that of previous studies. Results from KEYNOTE-B61 support the use of pembrolizumab plus lenvatinib as a first-line treatment option for these patients.Merck Sharp & Dohme (a subsidiary of Merck & Co, NJ, USA), and Eisai.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无奈狗完成签到,获得积分10
1秒前
piao完成签到,获得积分10
1秒前
MrChew完成签到 ,获得积分10
2秒前
香蕉觅云的应助被sukiii采纳,获得10
2秒前
3秒前
kiana完成签到,获得积分10
3秒前
钢筋炒煤球完成签到,获得积分10
4秒前
XF完成签到,获得积分10
4秒前
yinzhang5完成签到,获得积分10
4秒前
含蓄的之云完成签到,获得积分10
4秒前
全程都v回复v完成签到,获得积分10
4秒前
冷傲太英完成签到,获得积分10
4秒前
殷勤的帽子完成签到,获得积分10
5秒前
帅气香岚完成签到,获得积分20
5秒前
美好含巧完成签到,获得积分10
6秒前
Steve完成签到,获得积分10
6秒前
ffiu完成签到,获得积分10
6秒前
Skilixta完成签到,获得积分10
6秒前
吴煜阳完成签到,获得积分10
6秒前
Jane完成签到,获得积分10
7秒前
7秒前
Faith完成签到,获得积分10
7秒前
Ohh完成签到,获得积分10
7秒前
斯文大霖完成签到,获得积分10
7秒前
不善言辞的热心网友完成签到 ,获得积分10
7秒前
16601107082完成签到,获得积分20
7秒前
RAE完成签到,获得积分10
7秒前
hhhhh发布了新的文献求助10
7秒前
Qwe完成签到,获得积分10
7秒前
坚强的灵雁完成签到 ,获得积分10
7秒前
Ava的应助被悦耳的蜗牛采纳,获得10
8秒前
8秒前
yongjiao完成签到,获得积分10
8秒前
xusujuan完成签到,获得积分10
8秒前
2577完成签到 ,获得积分10
9秒前
淡定可燃冰完成签到,获得积分10
9秒前
狂野水壶完成签到 ,获得积分10
9秒前
白鸥完成签到 ,获得积分10
9秒前
9秒前
wtdai完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173580
求助须知:如何正确求助?哪些是违规求助? 9565737
关于积分的说明 21782083
捐赠科研通 7767775
什么是DOI,文献DOI怎么找? 3431604
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476870